Thank you, Dave.
X quarter, approval commercial each. made pediatric value pleased drivers to remain with in in broad and than both Slides X opportunity, main North to our IMCIVREE continued on our with focused regulatory the younger our progress development America ages on milestone X across on this are advancements We internationally, progress report out three we In X. quarter in We another steady and another and patients strong EU for have in shown programs.
execute global First, on as strategy. the continues commercial our to team noted,
new in continue excited MCXR the global make progress obesity trial. success our we two third, Second, with trials. and to Phase Phase I the of and we remain And hypothalamic ongoing II agonist III in likelihood about Phase
the Phase completed in We have year-end. the on remains trial the Phase to enrollment cohorts M&A track III leading by two trial and DAYBREAK II complete
Bardet-Biedl the market attended this the in BBS to not in-person and classic and Minneapolis, is more meeting and XXX see, Conference driven international, most is were to patients in years. hunger than first approval BBS. extent you with what which a what number that by those physicians. disease new remains rare to U.S. increasing you to striking More with attended The weeks BBS One of see the disease a relatively in post having the was $XX.X for expert. Foundation there quarter Revenues explain refrain the are I is. challenge. than invisible access tired members International the common to for remains family ago, predominantly Two all million, the me at doctor along Two but level who in four expert of obesity are years each aren't to syndrome the
goal, one managing head to getting did which opening the foundation diagnosis, the Of someone families, meet charge not an a patients the disease community. expert finding facing with disease. the include challenges the session, the from the attendees know rare In physician, and of they many their
of other to to for be we, the interact That centers and, drug. meeting as simply development and supporting not Instead, one has One members integrated experts, the with on on goal patients from more privileged having community Rhythm, most families importantly, it. the our care was of their focused is beginning been Rhythm and more more big part of community. focus the with alone. has biggest of feeling opportunities family, a selling were
the to half the X:X and on open-label for eight extension. to A are for the XXX the remains At cohort rolling with all placebo this brief right for remains titration our this enrolled revenue hypothalamic over the and their enrolled into up to remains the on difference BMI. XX% placebo-adjusted trial XXXX community and dropout follow. reminder, enrolled, obesity, point, low, high. trial is and and to How track the their patients, our rate enthusiasm calling first will therapeutic pivotal readout randomized XX% relate weeks drug do pivotal have Phase You growth? The ongoing reach revenues in for weeks protocol dose portion completed the exceedingly III has that a in the does family placebo-controlled trial over thing, first powered XX In show trial patients and dose. patient, a
interest, GLP-X on Of GLP-Xs these do institution, the entered patients approximately the We had patients is part these exercise from enrolled weight was their preceding as success. and diet were this on long trial enrolled of three not of we of what enroll They Of therapy. tried not as exercise the previously have diet GLP-X or to about formal trial trial. patients the active a care exclude with of experience received and patients cancel trial on only that of in patients XX% months. stable or did recognizing over allowed all without XX% design. as standard Patients almost tried for note,
patients to but In the to obesity patients may partly this response but Our may or overall GLP-Xs, will total patients we population X,XXX many the the with European of smaller, sustained Japan's we patient screening patients with actively number be use hypothalamic plus to and and cohort less percent position XX have these informed less. atrial much that cohort X,XXX initial have research and patients that States you ] XX-patient data to in which pivotal U.S. XX% dosed population, and estimates is estimate affect is our the benefit on sites the and community, patients despite cohort by GLP-X we with by Japan than the the engagement of are overall with where in and being have of for submissions. United also [ timing XX%, first This our par the some done, in Japan. on regulatory seek with us benefit with many four approval not of at from Japan, will be be European magnitude in enable Japanese regulatory
II I SAD, ascending cohorts of MAD, of in Our goal progressing made need in the in study, that the heart the two multiple the patient potentially single-ascending for next-generation weekly the the RM-XXX, and the agonist melanotide agonism MCX early portion trial the through designed avoid oral XX comes satisfying with Last two the measure advancing MCXR the a injectable the MCXR patient study, our dosing add dedicated simplifying regulatory is dose schedule. with higher agonist of avoiding we to dosing study hypothalamic The QTC regulatory We with Phase phase offset normal obesity. dose evaluating additional on the requirements this development SAD hyperpigmentation announced first in to are built path. portions thereby of of obesity. Phase trial LBXXXXX placebo-controlled healthy our in volunteers decision month, rhythm,
towards patients POMC/LEPR Bardet-Biedl for the X pleased with or were the Commission Finally, X syndrome old to authorization than deficiency. from expanded marketing In IMCIVREE to for we the European years receive less of track FDA U.S., the in year. to end for keeps we submission label the on expansion potential second of new us quarter, a the completed supplemental drug the this which application
for outcomes. it an have better approval previously treatable we early importantly, diagnosis expands to patients potential highlighted, this but population, enough modestly fortunate age the at As offer more a may get
severely May Two reduction genetic of the affected; takeaways trial on will defect on comorbidities key one, from intervention young that at Congress treatment data, Phase birth. one Slide two, at of can and as shown patients mean diseases European to obesity. as a which the BMI responded are obesity X, These at and patients they was X and in XX.X% model year. impact III an the with be long-term present the uniformly were: is with as well early modeling in presented share Yann in
early as possible. you start Given potential not to want benefit, why treatment the would as
to the American Jennifer? provide now call the to I'll turn Jennifer So over update. North
